Overview Dividends

(SNY) Sanofi - Ratings and Ratios

Exchange: NASDAQ • Country: France • Currency: USD • Type: Common Stock • ISIN: US80105N1054

Vaccines, Oncology, Immunology, Neurology, Rare Diseases

SNY EPS (Earnings per Share)

EPS Growth (3Y CAGR): 27.28%
EPS Trend (3Y Correlation): 0.6%

SNY Revenue

Revenue Growth (3Y CAGR): 5.20%
Revenue Trend (3Y Correlation): -4.5%

Risk via 10d forecast
Volatility	24.1%
Value at Risk 5%th	37.2%

Reward
Sharpe Ratio	0.24
Alpha Jensen	-2.79

Character
Hurst Exponent	0.301
Beta	0.371

Drawdowns 3y
Max DD	21.87%
Mean DD	8.41%

Description: SNY Sanofi September 25, 2025

Sanofi (NASDAQ:SNY) is a global biopharma company that discovers, develops, manufactures, and markets therapeutic products across several therapeutic areas, including immunology & inflammation, rare diseases, neurology, oncology, and vaccines. Its vaccine portfolio spans pediatric (polio, pertussis, Hib), respiratory syncytial virus, hexavalent combination vaccines, influenza, meningitis, and travel/endemic vaccines such as hepatitis A, typhoid, yellow fever, and rabies.

The firm maintains an extensive partnership network to augment its pipeline: a collaboration with Exscientia to co-develop up to 15 novel small-molecule candidates for oncology and immunology; agreements with ABL Bio (ABL301 for α-synucleinopathies), Innate Pharma (NK-cell engager targeting B7-H3), Blackstone Life Sciences (clinical development support), IGM Biosciences (IgM antibody platform), Kymera Therapeutics (IRAK4 degraders), Nurix Therapeutics (targeted protein degradation), Denali Therapeutics (systemic inflammatory diseases), Adagene (antibody discovery), Scribe Therapeutics (genome editing), and a co-promotion deal with Provention Bio for teplizumab. Sanofi also partners with Abu Dhabi’s Department of Health on global vaccine initiatives.

Key recent metrics (FY 2023) show revenue of €42.1 billion, with vaccines contributing roughly 15 % and a 9 % YoY increase in oncology sales driven by its Libtayo franchise. R&D expenditure remained steady at €6.5 billion (≈15 % of sales), reflecting continued investment in protein-degrader and gene-editing platforms. Sector-wide drivers that materially affect Sanofi’s outlook include an aging global population (projected to increase demand for chronic-disease therapeutics by ~3 % CAGR through 2030) and heightened vaccine spending post-COVID-19, which is expected to lift the overall vaccine market size to > $70 billion by 2028.

For a deeper quantitative assessment of SNY’s valuation and scenario-based risk/reward profile, the ValueRay platform provides a curated set of peer-adjusted multiples and forward-looking financial models.

SNY Stock Overview

Market Cap in USD	121,082m
Sub-Industry	Pharmaceuticals
IPO / Inception	2002-07-01
Return 12m vs S&P 500	-6.68%
Analyst Rating	4.18 of 5

SNY Dividends

Dividend Yield	4.26%
Yield on Cost 5y	5.33%
Yield CAGR 5y	3.83%
Payout Consistency	97.2%
Payout Ratio	51.5%

SNY Growth Ratios

CAGR	10.32%
CAGR/Max DD Calmar Ratio	0.47
CAGR/Mean DD Pain Ratio	1.23
Current Volume	1294.6k
Average Volume	2178k

Piotroski VR‑10 (Strict, 0-10) 4.5

Net Income (9.11b TTM) > 0 and > 6% of Revenue (6% = 2.53b TTM)

FCFTA 0.02 (>2.0%) and ΔFCFTA -1.65pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 4.60% (prev -36.66%; Δ 41.25pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.03 (>3.0%) and CFO 3.56b <= Net Income 9.11b (YES >=105%, WARN >=100%)

Net Debt (4.63b) to EBITDA (9.21b) ratio: 0.50 <= 3.0 (WARN <= 3.5)

Current Ratio 1.06 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (2.47b) change vs 12m ago -1.52% (target <= -2.0% for YES)

Gross Margin 72.56% (prev 69.43%; Δ 3.13pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 32.89% (prev 37.53%; Δ -4.64pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 8.21 (EBITDA TTM 9.21b / Interest Expense TTM 943.5m) >= 6 (WARN >= 3)

ValueRay F-Score (Strict, 0-100) 57.35

1. Piotroski 4.50pt = -0.50

2. FCF Yield 1.96% = 0.98

3. FCF Margin 5.07% = 1.27

4. Debt/Equity 0.18 = 2.48

5. Debt/Ebitda 0.50 = 2.31

6. ROIC - WACC (= 0.07)% = 0.09

7. RoE 12.36% = 1.03

8. Rev. Trend -4.47% = -0.34

9. EPS Trend 0.63% = 0.03

What is the price of SNY shares?

As of November 13, 2025, the stock is trading at USD 51.92 with a total of 1,294,579 shares traded.
Over the past week, the price has changed by +5.96%, over one month by +6.39%, over three months by +8.05% and over the past year by +8.14%.

Is Sanofi a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, Sanofi is currently (November 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 57.35 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SNY is around 52.27 USD . This means that SNY is currently overvalued and has a potential downside of 0.67%.

Is SNY a buy, sell or hold?

Sanofi has received a consensus analysts rating of 4.18. Therefore, it is recommended to buy SNY.

Strong Buy: 5
Buy: 3
Hold: 3
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the SNY price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	60.6	16.8%
Analysts Target Price	60.6	16.8%
ValueRay Target Price	57.3	10.4%

SNY Fundamental Data Overview November 07, 2025

Market Cap EUR = 104.43b (121.08b USD * 0.8625 USD.EUR)
P/E Trailing = 16.2791
P/E Forward = 9.9701
P/S = 2.6362
P/B = 1.4874
P/EG = 0.773
Beta = 0.371
Revenue TTM = 42.14b EUR
EBIT TTM = 7.75b EUR
EBITDA TTM = 9.21b EUR
Long Term Debt = 11.79b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 8.49b EUR (from shortTermDebt, last quarter)
Debt = 13.53b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.63b EUR (from netDebt column, last quarter)
Enterprise Value = 109.06b EUR (104.43b + Debt 13.53b - CCE 8.91b)
Interest Coverage Ratio = 8.21 (Ebit TTM 7.75b / Interest Expense TTM 943.5m)
FCF Yield = 1.96% (FCF TTM 2.13b / Enterprise Value 109.06b)
FCF Margin = 5.07% (FCF TTM 2.13b / Revenue TTM 42.14b)
Net Margin = 21.62% (Net Income TTM 9.11b / Revenue TTM 42.14b)
Gross Margin = 72.56% ((Revenue TTM 42.14b - Cost of Revenue TTM 11.56b) / Revenue TTM)
Gross Margin QoQ = 74.09% (prev 72.13%)
Tobins Q-Ratio = 0.84 (Enterprise Value 109.06b / Total Assets 129.79b)
Interest Expense / Debt = 1.68% (Interest Expense 227.0m / Debt 13.53b)
Taxrate = 19.38% (680.0m / 3.51b)
NOPAT = 6.25b (EBIT 7.75b * (1 - 19.38%))
Current Ratio = 1.06 (Total Current Assets 34.04b / Total Current Liabilities 32.10b)
Debt / Equity = 0.18 (Debt 13.53b / totalStockholderEquity, last quarter 73.26b)
Debt / EBITDA = 0.50 (Net Debt 4.63b / EBITDA 9.21b)
Debt / FCF = 2.17 (Net Debt 4.63b / FCF TTM 2.13b)
Total Stockholder Equity = 73.71b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.02% (Net Income 9.11b / Total Assets 129.79b)
RoE = 12.36% (Net Income TTM 9.11b / Total Stockholder Equity 73.71b)
RoCE = 9.06% (EBIT 7.75b / Capital Employed (Equity 73.71b + L.T.Debt 11.79b))
RoIC = 6.76% (NOPAT 6.25b / Invested Capital 92.41b)
WACC = 6.69% (E(104.43b)/V(117.97b) * Re(7.38%) + D(13.53b)/V(117.97b) * Rd(1.68%) * (1-Tc(0.19)))
Discount Rate = 7.38% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -81.65 | Cagr: -0.79%
[DCF Debug] Terminal Value 70.46% ; FCFE base≈2.95b ; Y1≈1.94b ; Y5≈885.5m
Fair Price DCF = 7.15 (DCF Value 17.41b / Shares Outstanding 2.44b; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 0.63 | EPS CAGR: 27.28% | SUE: 0.22 | # QB: 0
Revenue Correlation: -4.47 | Revenue CAGR: 5.20% | SUE: 0.30 | # QB: 0

Additional Sources for SNY Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle